Tango Therapeutics exits its August earnings event with short sellers accelerating rather than retreating, even as the borrow market simultaneously floods with new supply — a divergence that defines the stock's post-print setup.
Short interest jumped to 32.9% of the free float on August 11, up 9.3% in a single session and 13.4% on the week. That 33-point reading marks the highest level recorded in the trailing 30-day window, which itself saw shorts grow nearly 40%. To be clear about where this started: as recently as early July, SI ran closer to 22–23% of float, meaning bears have added roughly 10 percentage points of float in six weeks. The stock lost 10.3% on the week and 15.2% over the past month, now trading at $26.34. The borrow market, however, tells a striking counter-story. Availability surged to nearly 3,929% of existing short interest on August 11 — up from 916% the prior day — meaning the lending pool has expanded dramatically even as shorts pile in. Cost to borrow has ticked up about 15% on the week to 0.69%, but remains negligible in absolute terms. Bears can build and hold positions cheaply, with virtually no squeeze pressure from the lending market.
Options positioning has shifted modestly in the bearish direction. The put/call ratio moved to 0.54, slightly above its 20-day average of 0.50, with a z-score just above one — cautious but not extreme. The ORTEX short score has eased to 62.8 from a recent high near 65, partly reflecting the loosening borrow conditions offsetting the rising short interest. That factor score profile reinforces the picture: the short-score rank sits at just the 17th percentile, suggesting the short-side setup, while notable in absolute terms, is not yet flashing the kind of squeeze risk seen in more constrained names.
The Street remains constructive despite the price action. Guggenheim raised its target to $35 from $32 this morning while maintaining a Buy. JP Morgan initiated at Overweight with a $46 target in mid-July. Jefferies upgraded to Buy in late June, lifting its target from $27 to $60. The consensus mean target is $44.58 — nearly 70% above the current price. The bull case centres on vopimetostat's potential to meaningfully boost KRAS inhibitor efficacy in pancreatic cancer, underpinned by the Revolution Medicines partnership. Bears flag intensifying competition from Bristol Myers, IDEAYA, and AstraZeneca in both PRMT5 and KRAS, and point to the risk of negative data or FDA setbacks. The analyst recommendation divergence score ranks at the 93rd percentile, meaning the spread between bull and bear views is wider than almost any other name in the database.
Institutional ownership is dense at the top. RTW Investments holds 9.2% of shares, Adage Capital 8.9%, and BlackRock 8.6% — three of the top four holders added meaningfully in the March quarter. FMR and Vanguard both disclosed fresh or materially larger positions through June 30. That concentration of healthcare-specialist long-only money sits directly opposite the growing short book, setting up a structural tug-of-war. Insider activity adds a further wrinkle: divisional president Adam Crystal has sold stock in every month from April through August, totalling roughly $2.15 million net in 90 days. Each transaction carries a low significance score and the cadence suggests a scheduled plan rather than conviction selling, but the consistency warrants watching.
Earnings history provides relevant colour. The prior print on June 4 saw the stock fall 5.8% on day one before recovering sharply to a 38.9% gain over the following five sessions. The print before that, on May 15, produced a 17% one-day decline followed by a further 18.6% loss over five days. Two very different outcomes from two consecutive events. The next scheduled print is November 6. Until then, the central question is whether the growing short book reflects genuine fundamental concern about trial data and competitive positioning, or whether it represents a technically overleveraged position sitting on top of one of the more well-supported institutional registers in small-cap biotech.
See the live data behind this article on ORTEX.
Open TNGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
